This article is more than 5 years old. Information may no longer be current.

Aura Biosciences closes $30 million in Series C funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aura Biosciences has completed $30 million in Series C financing, according to a company press release.

Lundbeckfonden Ventures and Arix Bioscience led the funding, with the company’s current investors also participating, the release said.

The funding is expected to be used to advance clinical development of AU-011, a light-activated, targeted therapy for the treatment of ocular melanoma.

“This year has been one of incredible momentum for Aura, with interim positive data reported from our phase 1b/2 study of AU-011 and enthusiasm from key opinion leaders in ocular oncology across the country,” Elisabet de los Pinos, PhD, Aura founder and CEO, said in the release.